期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 341, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.jneuroim.2020.577184
关键词
Paraneoplastic syndrome; Immune checkpoint inhibitor; Anti-PD-1 inhibitor; Nivolumab, anti-Hu antibody; Neurologic immune related adverse events
We present an illustrative case of a 62-year-old woman with small cell lung cancer who developed progressive worsening of pre-existing anti-Hu antibody associated sensory neuronopathy after treatment with programmed cell death-1 (PD-1) inhibitor, nivolumab. We review the literature and identify 6 reported cases to understand the clinical outcomes of patients with anti-Hu paraneoplastic neurologic syndrome (PNS) treated with anti-PD-1 treatment. The PNS clinical spectrum comprised of encephalitis, a combination of sensory neuronopathy and anti-NMDAR encephalitis, isolated sensory neuronopathy, and encephalomyelitis. Immune checkpoint inhibitor have the potential to worsen pre-existing anti-Hu PNS and may promote the development of anti-Hu PNS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据